This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
AOP: 422
Title
Binding of SARS-CoV-2 to ACE2 in enterocytes leads to intestinal barrier disruption
Short name
Graphical Representation
Point of Contact
Contributors
- Laure-Alix Clerbaux
- Cataia Ives
Coaches
- Cinzia La Rocca
OECD Information Table
OECD Project # | OECD Status | Reviewer's Reports | Journal-format Article | OECD iLibrary Published Version |
---|---|---|---|---|
1.96 | Under Development |
This AOP was last modified on May 26, 2024 20:39
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Binding to ACE2 | August 30, 2023 20:36 |
SARS-CoV-2 cell entry | April 04, 2023 07:39 |
Increased SARS-CoV-2 production | June 14, 2022 08:49 |
Intestinal barrier, disruption | June 21, 2022 11:19 |
Interferon-I antiviral response, antagonized by SARS-CoV-2 | December 15, 2023 14:27 |
Binding to ACE2 leads to SARS-CoV-2 cell entry | February 07, 2023 23:24 |
SARS-CoV-2 cell entry leads to IFN-I response, antagonized | December 12, 2023 15:15 |
IFN-I response, antagonized leads to SARS-CoV-2 production | December 14, 2023 15:23 |
SARS-CoV-2 production leads to Disruption of the intestinal barrier | June 14, 2022 09:26 |
Sars-CoV-2 | September 09, 2022 05:09 |
Abstract
AOP Development Strategy
Context
AOP422 is developed within the CIAO project, "Modelling the Pathogenesis of COVID-19 Using the Adverse Outcome Pathway (AOP)". The overall goal is to organize and understand the vast amount of data that is constantly evolving as a result of the COVID-19 pandemic and identify uncertainties and knowledge gaps that may be missing using the AOP framework. Many AOPs were developed in the CIAO project, each AOP focusing on a specific element of the SARS-COV-2 virus responses in humans.
AOP422 focuses on the gastrointestinal disorders following SARS-CoV-2 infection of the enterocytes inducing disruption of intestinal barrier.
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
MIE | 1739 | Binding to ACE2 | Binding to ACE2 |
KE | 1738 | SARS-CoV-2 cell entry | SARS-CoV-2 cell entry |
KE | 1901 | Interferon-I antiviral response, antagonized by SARS-CoV-2 | IFN-I response, antagonized |
KE | 1847 | Increased SARS-CoV-2 production | SARS-CoV-2 production |
KE | 1931 | Intestinal barrier, disruption | Disruption of the intestinal barrier |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Binding to ACE2 leads to SARS-CoV-2 cell entry | adjacent | High | High |
SARS-CoV-2 cell entry leads to IFN-I response, antagonized | adjacent | Low | |
IFN-I response, antagonized leads to SARS-CoV-2 production | adjacent | Low | |
SARS-CoV-2 production leads to Disruption of the intestinal barrier | adjacent | Low | Low |
Network View
Prototypical Stressors
Name |
---|
Sars-CoV-2 |
Life Stage Applicability
Taxonomic Applicability
Sex Applicability
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Evidence Assessment
Known Modulating Factors
Modulating Factor (MF) | Influence or Outcome | KER(s) involved |
---|---|---|